Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Everest Medicines Limited

Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
From Everest Medicines Limited
Via ACN Newswire
Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access
From Everest Medicines Limited
Via ACN Newswire
Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan
From Everest Medicines Limited
Via ACN Newswire
NEFECON(R) Receives NMPA Approval for Production Expansion in China,as Everest Medicines Accelerates Accessibility and Capacity Efforts
From Everest Medicines Limited
Via ACN Newswire
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies
From Everest Medicines Limited
Via ACN Newswire
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million
From Everest Medicines Limited
Via ACN Newswire
Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy
From Everest Medicines Limited
Via ACN Newswire
Everest Medicines Announces the First Prescription of VELSIPITY(R) in the Greater Bay Area
From Everest Medicines Limited
Via ACN Newswire
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY
From Everest Medicines Limited
Via ACN Newswire
Everest Medicines Announces the First Prescription of VELSIPITY(R) Issued in Macau
From Everest Medicines Limited
Via ACN Newswire
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
From Everest Medicines Limited
Via ACN Newswire
Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong
From Everest Medicines Limited
Via ACN Newswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.